Fourteen-day infusion of ifosfamide in the management of advanced breast cancer refractory to protracted continuous infusion of 5-fluorouracil

V. Di Lauro, S. Spazzapan, D. Lombardi, C. Paolello, C. Scuderi, D. Crivellari, M. D. Magri, A. Veronesi

Research output: Contribution to journalArticle

Abstract

Aims and background: Ifosfamide is an active drug in advanced breast cancer. Short-term continuous infusion schedules have been evaluated with encouraging results. The aim of the study was to evaluate in patients with advanced breast cancer a 14-day infusion schedule previously tested at our center in soft tissue sarcomas. Methods: From July 1998 to February 2000, 26 consecutive patients with heavily pretreated breast cancer, progressing during protracted continuous infusion of fluorouracil, were treated with ifosfamide at the dose of 800 mg/m2/day for 14 consecutive days by means of an elastomeric pump via an indwelling Groshong catheter. The median age of the patients was 52 years (range, 32-67) and median PS was 1 (range, 1-3). All patients were pretreated with anthracyclines or taxanes; the median number of chemotherapy lines in the metastatic phase was 2 (range, 1-4). Predominant metastatic sites were soft tissues in 5 patients, lung in 6, liver in 7 and serosal cavities in 3. Results: Twenty-four patients were assessable for response. Two complete responses and 2 partial remissions were noted, for an overall 16.6% response rate. The duration of responses was 3+, 5, 8 and 10 months, respectively. Stabilization or minor response was observed in 2 more patients. The main toxic effect was myelosuppression (grade 1-2 in 15 patients, grade 3-4 in 4). Other toxicities included nausea in 14 patients (grade 3 in 2) and grade 1-2 vomiting in 2 patients. Hair loss or alopecia was universal. Conclusions: The regimen yielded some clinically useful responses with acceptable toxicity. Its evaluation in less advanced cases appears to be warranted.

Original languageEnglish
Pages (from-to)27-29
Number of pages3
JournalTumori
Volume87
Issue number1
Publication statusPublished - 2001

Keywords

  • Advanced breast cancer
  • Chemotherapy
  • Continuous infusion
  • Ifosfamide

ASJC Scopus subject areas

  • Cancer Research

Fingerprint Dive into the research topics of 'Fourteen-day infusion of ifosfamide in the management of advanced breast cancer refractory to protracted continuous infusion of 5-fluorouracil'. Together they form a unique fingerprint.

  • Cite this

    Di Lauro, V., Spazzapan, S., Lombardi, D., Paolello, C., Scuderi, C., Crivellari, D., Magri, M. D., & Veronesi, A. (2001). Fourteen-day infusion of ifosfamide in the management of advanced breast cancer refractory to protracted continuous infusion of 5-fluorouracil. Tumori, 87(1), 27-29.